Technical Analysis for GLSI - Greenwich LifeSciences, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Bollinger Band Squeeze | Range Contraction | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Earnings Movers | Other | 0.00% | |
Fell Below 20 DMA | Bearish | -0.07% | |
Fell Below 200 DMA | Bearish | -0.07% | |
Fell Below 50 DMA | Bearish | -0.07% | |
Bollinger Band Squeeze | Range Contraction | -0.07% | |
Death Cross | Bearish | -6.60% | |
200 DMA Support | Bullish | -6.60% |
Alert | Time |
---|---|
Up 1% | about 19 hours ago |
Possible NR7 | about 19 hours ago |
Possible Inside Day | about 19 hours ago |
Fell Below 10 DMA | 2 days ago |
20 DMA Support | 2 days ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/01/2024
Greenwich LifeSciences, Inc. Description
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein. In a randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months (p = 0.0338). Of the 138 patients that have been treated with GP2 to date over 4 clinical trials, GP2 treatment was well tolerated and no serious adverse events were observed related to GP2 immunotherapy. Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Acid Immunotherapy Surgery Cancer Treatment Breast Cancer Clinical Trial Treatment Of Breast Cancer Her2 Cancer Center Her2/Neu
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 21.44 |
52 Week Low | 8.0 |
Average Volume | 29,132 |
200-Day Moving Average | 14.14 |
50-Day Moving Average | 14.06 |
20-Day Moving Average | 13.68 |
10-Day Moving Average | 13.72 |
Average True Range | 0.64 |
RSI (14) | 45.05 |
ADX | 9.97 |
+DI | 20.88 |
-DI | 21.72 |
Chandelier Exit (Long, 3 ATRs) | 12.86 |
Chandelier Exit (Short, 3 ATRs) | 14.45 |
Upper Bollinger Bands | 14.44 |
Lower Bollinger Band | 12.93 |
Percent B (%b) | 0.34 |
BandWidth | 11.01 |
MACD Line | -0.09 |
MACD Signal Line | -0.11 |
MACD Histogram | 0.0178 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 13.85 | ||||
Resistance 3 (R3) | 13.87 | 13.75 | 13.78 | ||
Resistance 2 (R2) | 13.75 | 13.65 | 13.74 | 13.76 | |
Resistance 1 (R1) | 13.60 | 13.58 | 13.54 | 13.58 | 13.74 |
Pivot Point | 13.48 | 13.48 | 13.45 | 13.47 | 13.48 |
Support 1 (S1) | 13.32 | 13.37 | 13.26 | 13.30 | 13.14 |
Support 2 (S2) | 13.20 | 13.31 | 13.19 | 13.12 | |
Support 3 (S3) | 13.05 | 13.20 | 13.10 | ||
Support 4 (S4) | 13.03 |